Clinical Trial ECOGHEME2408


A 3-Arm Randomized Phase II Trial of Bendamustine-Rituximab (BR) Followed by Rituximab vs Bortezomib-BR (BVR) Followed by Rituximab vs BR Follwed by Lenalidomide/Rituximab in High Risk Follicular Lymphoma

Principal Investigator(s)

Nishitha Reddy


  • Protocol No. ECOGHEME2408
  • Open Date: 05/10/2011
  • Staging: Phase II
  • Age Group: Adults
  • Scope: National
  • Objective: To compare the complete remission (CR) rate of BR versus BVR as induction therapy. To compare the 1-year post-induction disease-free survival (DFS) rate with rituximab plus lenalidomide to rituximab alone as continuation therapy.
  • Disease Sites: Lymphoma
  • Therapies: Chemotherapy - cytotoxic; Molecular Targeted Agents / Immunotherapy / Biologics
  • Drugs: Bendamustine; Bortezomib (BTZ); Lenalidomide; Rituxan; Rituximab (Rituxan); VELCADE
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT01216683
  • Secondary Protocol No: E2408



Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.